Alle Storys
Folgen
Keine Story von Technische Universität München mehr verpassen.

Technische Universität München

New approach to sepsis therapy

TECHNICAL UNIVERSITY OF MUNICH

Corporate Communications Center

phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de

This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35210/

High resulution image: https://mediatum.ub.tum.de/1471894

NEWS RELEASE

Protein engineering extends the language of immune cells

Evolution of signaling molecules opens door to new sepsis therapy approaches

Small infections can be fatal: Millions of people die each year from sepsis, an overreaction of the immune system. A new immune signaling molecule, designed by a research team from the Technical University of Munich (TUM), now provides the basis for potential new approaches in sepsis therapy.

The numbers are alarming: According to estimates by the World Health Organization (WHO), around six million people die every year from sepsis. The disease, popularly called "blood poisoning", normally starts with a harmless infection.

If this triggers an excessive reaction of the immune system, the body's own tissue can be attacked and damaged. The overreaction eventually leads to a life-threatening collapse of the body's defenses. In Germany alone, more people die of sepsis than of AIDS, colon cancer and breast cancer combined.

Researchers around the world are on the search for new therapies - so far in vain. An interdisciplinary team from the fields of structural biology, immunology and cell biology has now, for the first time, successfully produced a protein that could balance the overshooting immune response.

The language of immune cells

In their work, the scientists were inspired by evolution: mice are well protected from sepsis by their immune systems. Here, interleukins - messengers, that mediate communication between the cells of the immune system - play a key role.

"The interleukins are the vocabulary with which immune cells communicate," explains Matthias Feige, Professor of Cellular Protein Biochemistry at the Technical University of Munich. The cells form these messenger molecules according to a very specific blueprint of individual amino acids. Their arrangement determines, which three-dimensional structure an interleukin adopts and, consequently, which information it transmits.

Humans and mice have similar, yet different vocabularies. The researchers discovered one striking difference in interleukin-27-alpha. This molecule can be released by cells of the mouse immune system - but not by human cells - and regulates immune cell function.

"Using computer models and cell biological experiments, we discovered that a single structurally important amino acid defines whether interleukin-27-alpha is released by cells of the immune system," explains Stephanie Müller, the first author of the study. "That gave us an idea about how we can engineer novel human interleukin proteins that are released by cells so that we can produce them biotechnologically."

Proteins with new functions from the laboratory

The team then prepared the modified interleukin in the laboratory and tested its biological functions - with very encouraging results: The engineered messenger molecule is recognized by human cells. First analyses suggest that it can indeed balance an overreaction of the immune system, making it a promising candidate for sepsis therapy.

"Our approach allowed us to rationally extend the language of immune cells by engineering a key signaling molecule. This provides us with an opportunity to modulate the reaction of immune cells in a targeted manner. Such a finding was only possible thanks to the close collaboration with immunologists and clinicians from TUM, the Université Sorbonne in Paris and the Helmholtz Zentrum Muenchen," says Feige. A patent for the new protein is already pending.

Publication:

Stephanie I. Müller, Antonie Friedl, Isabel Aschenbrenner, Julia Esser-von Bieren, Martin Zacharias, Odile Devergne, Matthias J Feige:

A folding switch regulates interleukin 27 biogenesis and secretion of its alpha subunit as a cytokine

PNAS, 16.01.2019 - DOI: 10.1073/pnas.1816698116

Link: https://www.pnas.org/content/early/2019/01/15/1816698116

More information:

The research was funded by the German Research Foundation (DFG) in the context of the Collaborative Research Center SFB 1035 and the Cluster of Excellence Center for Integrated Protein Science Munich (CIPSM). Matthias J. Feige is a Rudolf Mössbauer Tenure Track Professor and is supported by the TUM Institute for Advanced Study with funds from the Excellence Initiative and the European Union.

Additional funding was provided by the Marie Curie COFUND program of the European Union, the Helmholtz Association, the Studienstiftung des Deutschen Volkes, the Fondation ARC pour la recherche sur le Cancer and the Ligue Nationale contre le Cancer (France).

The research was carried out at the Technical University of Munich at the Department of Theoretical Biophysics (Physics Department), in the Laboratory for Cellular Protein Biochemistry (Faculty of Chemistry), the Center for Allergy and Environment (ZAUM) of the TU Munich and the Helmholtz Zentrum Muenchen, as well as at the Université Sorbonne in Paris.

High resolution images:

https://mediatum.ub.tum.de/1471894

Contact:

Prof. Dr. Matthias J. Feige

Technical University of Munich

Laboratory for Cellular Protein Biochemistry

Lichtenbergstr. 4, 85748 Garching, Germany

Tel.: +49 89 289 13667 - E-Mail: matthias.feige@tum.de

https://www.cell.ch.tum.de

The Technical University of Munich (TUM) is one of Europe's leading research
universities, with around 550 professors, 42,000 students, and 10,000 academic
and non-academic staff. Its focus areas are the engineering sciences, natural
sciences, life sciences and medicine, combined with economic and social
sciences. TUM acts as an entrepreneurial university that promotes talents and
creates value for society. In that it profits from having strong partners in
science and industry. It is represented worldwide with the TUM Asia campus in
Singapore as well as offices in Beijing, Brussels, Cairo, Mumbai, San Francisco,
and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von
Linde, and Rudolf Mößbauer have done research at TUM. In 2006 and 2012 it won
recognition as a German "Excellence University." In international rankings, TUM
regularly places among the best universities in Germany. www.tum.de
Weitere Storys: Technische Universität München
Weitere Storys: Technische Universität München
  • 21.01.2019 – 17:04

    TUM is Germany's strongest university in business sciences

    TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/detail/article/35187/ NEWS RELEASE TUM is Germany's strongest university in business sciences "WirtschaftsWoche Ranking": Prof. Helmut Krcmar best business researcher The Technical University of Munich (TUM) is the ...

  • 17.01.2019 – 15:32

    Models of life: Artificially produced cells communicate with each other

    TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35181/ High resulution images and video: https://mediatum.ub.tum.de/1471327 NEWS RELEASE Models of life Artificially produced cells communicate with ...